Clinical Study Results
What adverse reactions happened during this study?
The most common adverse reaction was increased levels of liver proteins called ALT, AST, and
GGT.
The adverse reactions below happened in 25% or more of the participants. This was 9 or
more out of 33 participants. There were other adverse reactions, but these happened in fewer
participants.
Most common adverse reactions
MEDI3726
Adverse reactions (out of 33 participants)
Increased levels of a liver protein called ALT 36.4% (12)
Increased levels of a liver protein called AST 33.3% (11)
Increased levels of a liver protein called GGT 30.3% (10)
Fatigue 30.3% (10)
Fluid build-up in the lungs 27.3% (9)
How has this study helped patients and researchers?
This study helped researchers learn more about how safe MEDI3726 was to take for participants
with mCRPC.
Researchers look at the results of many studies to decide which treatments work best and are
safest. This summary shows only the main results from this one study. Other studies may provide
new information or different results.
Further clinical studies with MEDI3726 are not planned for prostate cancer.
7